Dyne Therapeutics
114 hedge funds and large institutions have $537M invested in Dyne Therapeutics in 2023 Q3 according to their latest regulatory filings, with 10 funds opening new positions, 47 increasing their positions, 32 reducing their positions, and 14 closing their positions.
3,615% more call options, than puts
Call options by funds: $3.05M | Put options by funds: $82K
47% more repeat investments, than reductions
Existing positions increased: 47 | Existing positions reduced: 32
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
3.36% less ownership
Funds ownership: 101.51% → 98.15% (-3.4%)
3% less funds holding
Funds holding: 118 → 114 (-4)
19% less capital invested
Capital invested by funds: $666M → $537M (-$129M)
29% less first-time investments, than exits
New positions opened: 10 | Existing positions closed: 14
Top Buyers
| 1 |
VC
Vivo Capital
Palo Alto,
California
|
+$4.93M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
+$4.78M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$4.31M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$3.61M |
| 5 |
JP Morgan Chase
New York
|
+$3.26M |
Top Sellers
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$8.99M |
| 2 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
-$6.16M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$5.63M |
| 4 |
Goldman Sachs
New York
|
-$5.4M |
| 5 |
Norges Bank
Oslo,
Norway
|
-$2.2M |
DYN Hedge Fund Activity: Q3 2023 in Review
114 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Dyne Therapeutics (DYN) for Q3 2023, worth a combined $537M — down 19% from $666M a quarter earlier.
Sellers outnumbered buyers: 14 funds closed out of DYN and 10 opened new positions — a net loss of 4 holders — while 32 trimmed existing stakes and 47 added.
The largest buyer was Vivo Capital, adding an estimated $4.93M. The largest seller was EcoR1 Capital, exiting entirely with an estimated $8.99M sold.
- 114 institutional investors held Dyne Therapeutics (DYN) as of Q3 2023, down from 118 in Q2 2023.
- Funds reported $537M of Dyne Therapeutics stock for Q3 2023, down 19% quarter-over-quarter.
- 10 funds opened new Dyne Therapeutics positions in Q3 2023 and 14 closed out, a net change of -4 holders.
- The largest Dyne Therapeutics buyer in Q3 2023 was Vivo Capital, an estimated $4.93M added.
- The largest Dyne Therapeutics seller in Q3 2023 was EcoR1 Capital, an estimated $8.99M sold.
Based on aggregated 13F filings for Q3 2023.